Pharma funds attract inflows | Value Research It has been a bitter investment but investors want more! Despite a discouraging performance by three

Best Funds for 2023: Handpicked Mutual Funds to build a winning portfolio.
(₹1,499 ₹999)

Buy Now Buy Now right-arrow

Pharma funds attract inflows

It has been a bitter investment but investors want more! Despite a discouraging performance by three

It has been a bitter investment but investors want more! Despite a discouraging performance by three pharma funds since launch in 1999, fresh investments have continued to pour in, largely driven by the long-term potential for the sector. Assets under management for three funds have seen an average growth of 30.52 per cent in the current year despite sharp erosion in net asset values. For instance, the pharma funds from Kothari, UTI and SBI Mutual Funds have seen an average fall of 30.48 per cent in the year-to-date period (ended October 31, 2000). Worse, none of the funds have paid any dividend since launch in 1999 with NAVs of both KP and SBI Magnum Pharma currently ruling below par. Only UTI Pharma has given a positive (though paltry) return of 0.44 per cent since launch in June 1999.

For a sample of growth in unit capital, consider this. The unit capital of Kothari Pioneer Pharma has vaulted by over 90 per cent from Rs 28 crore in April 1999 to Rs 54.54 crore on September 29 2000. The assets under management, despite a below par NAV, are at Rs 51.71 crore against Rs 25.77 crore in April 1999. Fresh investments have also come thick and fast in UTI Pharma, with the unit capital racing from Rs 18.80 crore in September 1999 to Rs 66.40 crore.

While the inflows into pharma funds would surely pale in comparison to the mad rush for the flamboyant technology funds earlier this year, the fresh investments nonetheless highlight the conviction for the pharmaceutical sector. While the sector had underperformed the markets last year with nearly flat sales growth, the second quarter has seen pharma companies bounce back with largely impressive results. The pharma sector has seen a near 20 per cent jump in sales with the bottomline growing by over 30 per cent in the second quarter. Apart from the steady growth, the highly fragmented sector (with over 20,000 companies) offers a tremendous opportunity for consolidation with mergers and acquisitions. This would surely add to returns from the sector in the long run.

However, fresh investors in pharma funds should not expect dramatic returns and need to be patient with their investments with the pharma sector beating the broad market indices in the long-term. For instance, the i-SEC Pharma index has seen an annualised gain of 69.41 per cent since launch in 1996 against a 7.17 per cent return by Nifty Total Return Index. Currently, the pharma funds are available at close to par values and offer a good buying opportunity. After all, medicines are a human being's most pressing need!

Pharma Brigade Rolls On
    Unit Capital (Rs cr.)  Unit Capital*  Returns (in %)
   (latest)  (since launch)
  KP Pharma 54.54 28.6 -3.37
  SBI Magnum Pharma 24.99 2.07 -2.87
  UTI Pharma & Healthcare 66.4 18.8 0.44
* first available figures

Other Categories